Satellos Bioscience Inc. MSLE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +13.95%
- 1 year
- +3.08%
- Open
- 6.68
- Prev close
- 6.82
- Mkt cap
- 142.15M
- Vol
- 30.78K
- Avg vol
- 42.12K
- EPS
- -1.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.43
- High
- 6.93
News
-
3 weeks ago benzinga.com
Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $24.
-
3 weeks ago benzinga.com
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that…
-
1 month ago benzinga.com
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment…
1 month ago defenseworld.net
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
Shares of Satellos Bioscience Inc. (NASDAQ: MSLE - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com…
-
1 month ago benzinga.com
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
-
2 months ago benzinga.com
Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18
HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $11 to $18.
3 months ago benzinga.com
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD)
3 months ago benzinga.com
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
-
3 months ago benzinga.com
Satellos Bioscience Announces Six-Month Interim Data From TRAILHEAD Evaluating SAT-3247 In Adults With Duchenne Muscular Dystrophy; All Four Participants Showed Decline In Fat Fraction As Measured By MRI
Fat fraction mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle compositionAll four participants showed an increase in TE99C, a measure of…
-
4 months ago benzinga.com
Satellos Gets FDA Fast Track Status For Duchenne Drug
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced
4 months ago globenewswire.com
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines…
5 months ago globenewswire.com
Satellos to Participate in Upcoming Investor Conferences
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $11 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $11 price target.
-
5 months ago benzinga.com
Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.
-
6 months ago benzinga.com
Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.
6 months ago 247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will…
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $11
HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy and raises the price target from $1.2 to $11.
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago benzinga.com
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.
-
7 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Satellos Bioscience with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Overweight rating.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session